FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386371796> ?p ?o ?g. }

• W4386371796 endingPage "4356" @default.
• W4386371796 startingPage "4356" @default.
• W4386371796 abstract "Many cancer patients still lack effective treatments, and pre-existing or acquired resistance limits the clinical benefit of even the most advanced medicines. Recently, much attention has been given to the role of metabolism in cancer, expanding from the Warburg effect to highlight unique patterns that, in turn, may improve diagnostic and therapeutic approaches. Our recent metabolomics study revealed that ribitol can alter glycolysis in breast cancer cells. In the current study, we investigate the combinatorial effects of ribitol with several other anticancer drugs (chrysin, lonidamine, GSK2837808A, CB-839, JQ1, and shikonin) in various breast cancer cells (MDA-MB-231, MCF-7, and T-47D). The combination of ribitol with JQ1 synergistically inhibited the proliferation and migration of breast cancer cells cell-type dependently, only observed in the triple-negative MDA-MB-231 breast cancer cells. This synergy is associated with the differential effects of the 2 compounds on expression of the genes involved in cell survival and death, specifically downregulation in c-Myc and other anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1), but upregulation in p53 and cytochrome C levels. Glycolysis is differentially altered, with significant downregulation of glucose-6-phosphate and lactate by ribitol and JQ1, respectively. The overall effect of the combined treatment on metabolism and apoptosis-related genes results in significant synergy in the inhibition of cell growth and induction of apoptosis. Given the fact that ribitol is a metabolite with limited side effects, a combined therapy is highly desirable with relative ease to apply in the clinic for treating an appropriate cancer population. Our results also emphasize that, similar to traditional drug development, the therapeutic potential of targeting metabolism for cancer treatment may only be achieved in combination with other drugs and requires the identification of a specific cancer population. The desire to apply metabolomic intervention to a large scope of cancer types may be one of the reasons identification of this class of drugs in a clinical trial setting has been delayed." @default.
• W4386371796 created "2023-09-02" @default.
• W4386371796 creator A5006600392 @default.
• W4386371796 creator A5010688100 @default.
• W4386371796 creator A5012762435 @default.
• W4386371796 creator A5044448405 @default.
• W4386371796 date "2023-09-01" @default.
• W4386371796 modified "2023-09-27" @default.
• W4386371796 title "Metabolic Reprogramming by Ribitol Expands the Therapeutic Window of BETi JQ1 against Breast Cancer" @default.
• W4386371796 cites W1073897353 @default.
• W4386371796 cites W1582429156 @default.
• W4386371796 cites W1603456871 @default.
• W4386371796 cites W1981004520 @default.
• W4386371796 cites W1993454901 @default.
• W4386371796 cites W2003570457 @default.
• W4386371796 cites W2028897202 @default.
• W4386371796 cites W2053617736 @default.
• W4386371796 cites W2058218780 @default.
• W4386371796 cites W2086184634 @default.
• W4386371796 cites W2104840184 @default.
• W4386371796 cites W2105391162 @default.
• W4386371796 cites W2117692326 @default.
• W4386371796 cites W2130503287 @default.
• W4386371796 cites W2159422067 @default.
• W4386371796 cites W2171990088 @default.
• W4386371796 cites W2176431841 @default.
• W4386371796 cites W2237475663 @default.
• W4386371796 cites W2519942994 @default.
• W4386371796 cites W2568300053 @default.
• W4386371796 cites W2586265133 @default.
• W4386371796 cites W2617901375 @default.
• W4386371796 cites W2738828769 @default.
• W4386371796 cites W2752975844 @default.
• W4386371796 cites W2789509782 @default.
• W4386371796 cites W2883733371 @default.
• W4386371796 cites W2888472805 @default.
• W4386371796 cites W2957986133 @default.
• W4386371796 cites W2969175364 @default.
• W4386371796 cites W2973850435 @default.
• W4386371796 cites W2999764480 @default.
• W4386371796 cites W3009367721 @default.
• W4386371796 cites W3011535475 @default.
• W4386371796 cites W3014208390 @default.
• W4386371796 cites W3040017248 @default.
• W4386371796 cites W3048887655 @default.
• W4386371796 cites W3116902555 @default.
• W4386371796 cites W3128646645 @default.
• W4386371796 cites W4311579376 @default.
• W4386371796 doi "https://doi.org/10.3390/cancers15174356" @default.
• W4386371796 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37686632" @default.
• W4386371796 hasPublicationYear "2023" @default.
• W4386371796 type Work @default.
• W4386371796 citedByCount "0" @default.
• W4386371796 crossrefType "journal-article" @default.
• W4386371796 hasAuthorship W4386371796A5006600392 @default.
• W4386371796 hasAuthorship W4386371796A5010688100 @default.
• W4386371796 hasAuthorship W4386371796A5012762435 @default.
• W4386371796 hasAuthorship W4386371796A5044448405 @default.
• W4386371796 hasBestOaLocation W43863717961 @default.
• W4386371796 hasConcept C104317684 @default.
• W4386371796 hasConcept C109156525 @default.
• W4386371796 hasConcept C121608353 @default.
• W4386371796 hasConcept C126322002 @default.
• W4386371796 hasConcept C127561419 @default.
• W4386371796 hasConcept C1491633281 @default.
• W4386371796 hasConcept C181199279 @default.
• W4386371796 hasConcept C185592680 @default.
• W4386371796 hasConcept C190283241 @default.
• W4386371796 hasConcept C20251656 @default.
• W4386371796 hasConcept C2780301084 @default.
• W4386371796 hasConcept C502942594 @default.
• W4386371796 hasConcept C530470458 @default.
• W4386371796 hasConcept C55493867 @default.
• W4386371796 hasConcept C62231903 @default.
• W4386371796 hasConcept C71924100 @default.
• W4386371796 hasConcept C77255625 @default.
• W4386371796 hasConcept C86803240 @default.
• W4386371796 hasConcept C96232424 @default.
• W4386371796 hasConceptScore W4386371796C104317684 @default.
• W4386371796 hasConceptScore W4386371796C109156525 @default.
• W4386371796 hasConceptScore W4386371796C121608353 @default.
• W4386371796 hasConceptScore W4386371796C126322002 @default.
• W4386371796 hasConceptScore W4386371796C127561419 @default.
• W4386371796 hasConceptScore W4386371796C1491633281 @default.
• W4386371796 hasConceptScore W4386371796C181199279 @default.
• W4386371796 hasConceptScore W4386371796C185592680 @default.
• W4386371796 hasConceptScore W4386371796C190283241 @default.
• W4386371796 hasConceptScore W4386371796C20251656 @default.
• W4386371796 hasConceptScore W4386371796C2780301084 @default.
• W4386371796 hasConceptScore W4386371796C502942594 @default.
• W4386371796 hasConceptScore W4386371796C530470458 @default.
• W4386371796 hasConceptScore W4386371796C55493867 @default.
• W4386371796 hasConceptScore W4386371796C62231903 @default.
• W4386371796 hasConceptScore W4386371796C71924100 @default.
• W4386371796 hasConceptScore W4386371796C77255625 @default.
• W4386371796 hasConceptScore W4386371796C86803240 @default.
• W4386371796 hasConceptScore W4386371796C96232424 @default.
• W4386371796 hasIssue "17" @default.

• next